The apoAI-CIII-AIV gene cluster

Atherosclerosis

Volumn 157, Issue 1, 2001, Pages 1-11

  Groenendijk, Martine ^a   Cantor, Rita M ^b   De Bruin, Tjerk W A ^c   Dallinga Thie, Geesje M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

A IV; Apolipoproteins A I; C III; Familial combined hyperlipidemia; Polymorphism

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; DNA; HIGH DENSITY LIPOPROTEIN; LIPID; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; ASSOCIATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE CLUSTER; GENE LOCATION; GENE MUTATION; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN A-I; GENOME, HUMAN; HUMANS; MULTIGENE FAMILY;

EID: 0034974758     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00539-1     Document Type: Review

References (152)

1. Apolipoprotein multigene family: Tandem organization of human apolipoprotein AI, CIII, and AIV genes
2. Linkage of human apolipoproteins A-I and C-III genes
3. Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4)
4. Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation
5. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment
6. Transcriptional regulation of the human apolipoprotein genes apoB, apoCIII, and apoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2 and EAR-3
7. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat
8. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: Relationship to plasma concentration of high density lipoproteins
9. Introduction to the plasma lipoproteins
10. A protein cofactor of lecithin:cholesterol acyltransferase
11. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: Cholesterol acyltransferase
12. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
13. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice
14. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
15. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
16. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
17. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
18. Human apolipoprotein A-I-C-III gene complex is located on chromosome 11
19. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
20. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III
21. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
22. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins
23. Modulation of lipoprotein lipase activity by apolipoproteins: Effect of apolipoprotein CIII
24. The low-density lipoprotein receptor-related protein: Double agent or decoy?
25. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver
26. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E
27. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: Modulation by apolipoprotein E and apolipoprotein C
28. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice
29. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice
30. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice
31. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
32. A mouse model with features of familial combined hyperlipidemia
33. Characterization of the apolipoproteins of rat plasma lipoproteins
34. An apolipoprotein homolog of rat apolipoprotein A-IV in human plasma
35. Isolation and characterization of an apoprotein from the d less than 1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein
36. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV
37. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma
38. Distribution of apolipoprotein A-IV in human plasma
39. Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins
40. Distribution of apolipoprotein A-IV among lipoprotein subclasses in rat serum
41. Familial apolipoprotein A-I, C-III, A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11
42. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells
43. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum
44. Distribution of apolipoprotein A-IV between the lipoprotein and the lipoprotein-free fractions of rat plasma: Possible role of lecithin:cholesterol acyltransferase
45. Activation of lecithin: Cholesterol acyltransferase by human apolipoprotein A-IV
46. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation
47. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior
48. A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidemic and normal individuals
49. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24
50. DNA polymorphisms in and around the apo-AI-CIII genes and genetic hyperlipidemias
51. Apolipoprotein AI-CIII-AIV gene cluster in familial combined hyperlipidemia: Effects on LDL-cholesterol and apolipoproteins B and CIII
52. Linkage disequilibrium of three polymorphic RFLP markers in the apolipoprotein AI-CIII gene cluster on chromosome 11
53. Human apolipoprotein A-I gene promoter polymorphism: Association with hyperalphalipoproteinemia
54. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations
55. A polymorphism (G to A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency
56. The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency
57. Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition
58. Polymorphism in the promoter region of the apolipoprotein A-I gene associated with differences in apolipoprotein A-I levels: The European Atherosclerosis Research study
59. Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein A-I gene is associated with elevated serum apolipoprotein A-I levels in Chinese non-smokers
60. Association of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses
61. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking status
62. Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol
63. C to T and/or G to A transitions are responsible for loss of a MspI restriction site at the 5′-end of the human apolipoprotein AI gene
64. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease
65. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia
66. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease
67. The 3′-flanking region shared by the human apolipoprotein AI and CIII gene regulates gene expression in cooperation with 5′-flanking elements
68. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia
69. DNA polymorphism adjacent to human apoprotein A-I gene: Relation to hypertriglyceridaemia
70. Linkage disequilibrium of the apo AI-CIII-AIV gene cluster and their relationship to plasma triglyceride, apolipoprotein AI and CIII levels in Koreans
71. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: Detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations
72. A PvuII polymorphism in the 5′ flanking region of the apolipoprotein A-IV gene: Its use to study genetic variation determining serum lipid and apolipoprotein concentration
73. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease
74. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII
75. Effect of apolipoprotein C-II and C-III levels in hyperlipoproteinemia
76. An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis
77. Deoxyribonucleic acid polymorphism in the apolipoprotein AI-CIII gene cluster. Associations with hypertriglyceridemia
78. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ UTR polymorphisms
79. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia
80. Hypertriglyceridemia and the apolipoprotein CIII gene locus: Lack of association with the variant insulin response element in Italian school children
81. Genetic markers in the apoAI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis
82. Haplotypes identified by DNA restriction-fragment-length polymorphisms in the A-I C-III A-IV gene region and hypertriglyceridemia
83. DNA polymorphic patterns and haplotype arrangements of the apo A-I, apoC-III, apo A-IV gene cluster in different ethnic groups
84. Strong association of a single nucleotide substitution in the 3′-untranslated region of the apolipoprotein-CIII gene with common hypertriglyceridemia in Arabs
85. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population
86. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico
87. Association between genetic variations of apo Al-CIII-AIV cluster gene and hypertriglyceridemic subjects
88. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease
89. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects
90. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia
91. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex
92. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia
93. Association between genetic variation at the apo AI-CIII-AIV gene cluster and familial combined hyperlipidemia
94. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia
95. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familiar combined hyperlipidemia
96. Genetic factors affecting the consistency and magnitude of changes in plasma cholesterol in response to dietary challenge
97. The apolipoprotein AI-CIII-AIV gene cluster: Sequence of the apoCIII-apoAIV intergenic region
98. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3′ to the gene in the promoter of the adjacent convergently transcribed apoC-III gene
99. Characterization of an enhancer element in the human apolipoprotein C-III gene that regulates human apolipoprotein A-I gene expression in the intestinal epithelium
100. The apolipoprotein A-I/C-III/A-IV gene cluster: ApoC-III and ApoA-IV expression is regulated by two common enhancers
101. Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements-Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites
102. Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene
103. Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4
104. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human apoCIII gene
105. Promoter elements and factors required for hepatic and intestinal transcription of the human apoCIII gene
106. Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene
107. Regulation of gene expression by insulin
108. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
109. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians
110. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France
111. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls
112. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests
113. Genetic variants of group A apolipoproteins. Rapid methods for screening and characterization without ultracentrifugation
114. Apolipoprotein A-IV polymorphism in man
115. The mutation causing the common apolipoprotein A-IV polymorphism is a glutamine to histidine substitution of amino acid 360
116. Three genetic variants of human plasma apolipoprotein A-IV
117. Human apolipoprotein A-IV polymorphism: Frequency and effect on lipid and lipoprotein levels
118. Molecular basis for apo A-IV polymorphisms
119. A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127
120. DNA polymorphisms of human apolipoprotein A-IV gene: Frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population
121. Apolipoprotein A-IV polymorphism and its effect on plasma lipid and apolipoprotein concentrations
122. Frequency and effect of human apolipoprotein A-IV polymorphism on lipid and lipoprotein levels in an Icelandic population
123. Genetic polymorphism of apolipoprotein A-IV in five different regions of Europe. Relations to plasma lipoproteins and to history of myocardial infarction: The EARS study. European Atherosclerosis Research Study
124. Nonsynonymous polymorphic sites in the apolipoprotein (apo) A-IV gene are associated with changes in the concentration of apo B- and apo A-I-containing lipoproteins in a normal population
125. Apolipoprotein A-IV polymorphism, and its role in determining variation in lipoprotein-lipid, glucose and insulin levels in normal and non-insulin-dependent individuals
126. ApoA-IV polymorphism associated with myocardial infarction in obese NIDDM patients
127. Genetic variation at the ApoA-IV gene locus and response to diet in familial hypercholesterolemia
128. ApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering
129. Two common polymorphisms in the Apo A-IV coding gene: Their evolution and linkage disequilibrium
130. Two polymorphisms for amino acid substitutions in the APOA4 gene
131. Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II
132. Influence of two apo A4 polymorphisms at codons 347 and 360 on non-fasting plasma lipoprotein-lipids and apolipoproteins in Asian Indians
133. Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus
134. A common deletion polymorphism in the apolipoprotein A4 gene and its significance in lipid metabolism
135. Human plasma apolipoproteins A-IV-0 and A-IV-3 Molecular basis for two rare variants of apolipoprotein A-IV-1
136. Molecular basis of a unique African variant (A-IV 5) of human apolipoprotein A-IV and its significance in lipid metabolism
137. Hyperlipidemia in coronary heart disease. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
138. Genetics and molecular biology of familial combined hyperlipidemia
139. Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia
140. Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype
141. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype
142. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23
143. Linkage of a candidate gene locus to familial combined hyperlipidemia-Lecithin:cholesterol acyltransferase on 16q
144. DNA polymorphism haplotypes of the human apolipoprotein apoAI-apoC3-apoA4 gene cluster
145. Linkage disequilibrium of the Apo AI-CIII-AIV gene cluster and their relationship to plasma triglyceride, apolipoprotein AI and CIII levels in Koreans
146. Extended haplotypes and linkage disequilibrium between 11 markers at the APOA1-C3-A4 gene cluster on chromosome 11
147. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia
148. Genetic variation in the apolipoprotein A-IC-IIIA-IV gene cluster and coronary heart disease
149. Variation at the apolipoprotein(apo)AI-CIII AIV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian children
150. DNA polymorphisms of apolipoprotein AII and AI-CIII-AIV genes: A study in men selected for differences in high-density-lipoprotein cholesterol concentration
151. New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia
152. Two polymorphisms in the ApoA-IV gene and familial combined hyperlipidemia